PharmaTher Holdings Ltd. (PHRRF)
- GlobeNewswire
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch
Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and pharmacokinetic profiles Pursuing Phase 2 clinical studies in treatment-resistant depression and pain indications in Q4-2022 TORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has successfully complet
- GlobeNewswire
PharmaTher Announces Positive Results from Study of KETABET™ for Depression
KETABET™ (Ketamine and Betaine) shown effectiveness as measured by the Clinician Administered Dissociative States Scale Study results are adequate to give an effect size in powering a placebo-controlled clinical study PharmaTher planning a Phase 2 clinical study to incorporate KETABET™ in its proprietary microneedle patch for depression TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine ph
- GlobeNewswire
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
CCBIO’s Felice Dose on-body wearable device CCBIO’s Felice Dose on-body wearable device CCBIO’s Felice Dose on-body wearable device prototype worn on a person CCBIO’s Felice Dose on-body wearable device prototype worn on a person Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher aims to become a leader in specialty ketamine products for mental health, neurological and pain disorders TORONTO,
